Quad Technologies LLC

Invivotek LLC is a fully integrated Contract Research Organization (CRO) based in Trenton, NJ, specializing in providing comprehensive drug discovery services to support clients' research programs from target discovery to clinical trials. They offer a wide range of pre-clinical services, including the evaluation of test therapeutics and phenotypic characterization of genetically modified rodent models of human disease. With expertise in areas such as Immunology and Inflammation, Diabetes, Cardiovascular, Obesity, Neurodegenerative disorders, and Cancer, Invivotek utilizes in vivo testing capabilities supported by biochemical and molecular biology techniques to study the mechanism of action of potential therapeutics and explore drug efficacy biomarkers. As a proud member of Genesis Drug Discovery Development (GD3), Invivotek collaborates with this fully integrated CRO to provide comprehensive support throughout the drug discovery process, from target discovery to IND filing and managing Phase I-III clinical trials. Their portfolio includes both custom and standard pre-clinical services, offering bioassays designed to support in vivo testing of potential therapeutics. With a focus on traditional and genetically modified rodent models, Invivotek's services enable clients to gain valuable insights into the efficacy and mechanism of action of their test therapeutics, contributing to the advancement of drug discovery and development.Generated from the website

UroGen Pharma Ltd is a biotech company based in Princeton, NJ, dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. Their groundbreaking therapies and clinical pipeline aim to revolutionize the treatment of these cancers by maximizing the potential benefit of local delivery through their novel RTGel technology, offering transformative, nonsurgical approaches to patients. UroGen is at the forefront of a transformative shift in urothelial and specialty cancer treatment, moving away from invasive surgeries towards nonsurgical means. Their first commercial product, JELMYTO mitomycin for pyelocalyceal solution, is the first and only FDA-approved nonsurgical treatment of its kind, utilizing their RTGel technology. With a focus on fundamentally changing the treatment paradigm, UroGen is committed to providing noninvasive therapeutic options for some of the most devastating cancers.Generated from the website

Genmab Inc is a leading international biotech company with a strong focus on developing innovative antibody medicines for the treatment of cancer and other serious diseases. With headquarters in Denmark and offices in the Netherlands, the United States, and Japan, Genmab employs over 2,000 people globally. Their mission is to transform the lives of patients by developing knock-your-socks-off antibody medicines that have a profound impact on healthcare by 2030. Genmab's expertise lies in antibody technology platforms, translational research, and data science, which enable them to discover and develop novel medicines. They collaborate with healthcare professionals, patients, and investigators to conduct clinical trials and collaborative studies, ensuring the safety and efficacy of their products. Committed to corporate governance and integrity, Genmab encourages open communication and reporting of any concerns related to their business. Joining their team means being part of a mission to revolutionize cancer treatment and contribute to the future of healthcare.Generated from the website